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INTRODUCTION
What is aspirin-exacerbated respiratory disease?
Aspirin-exacerbated respiratory disease (AERD) is a clinical 
tetrad of nasal polyps, chronic hypertrophic eosinophilic sinus-
itis, asthma and sensitivity to any medication that inhibits cy-
clooxygenase-1 (COX-1) enzymes, namely aspirin and other 
nonsteroidal anti-inflammatory drugs (NSAIDs) (Table 1).
1,2 In-
gestion of aspirin, and most NSAIDs, results in a spectrum of 
upper and/or lower respiratory reactions, to include rhinitis, 
conjunctivitis, laryngospasm and bronchospasm.
1,2 AERD af-
fects 0.3-0.9% of the general population, but the prevalence ris-
es to 10-20% of asthmatics and up to 30-40% in those asthmat-
ics with nasal polyposis.
3-7 The average age of onset is 34 years 
in a US study and is thought to be acquired between teenage to 
middle adulthood years with no ethnic predilection and rare 
familial associations.
3-7 AERD is more commonly reported in 
females (57% vs. 43%).
7,8
Clinical features of AERD
AERD has been described as “Samter’s triad, aspirin induced 
asthma, aspirin sensitive asthma and aspirin hypersensitivity” .
1,9 
Despite the fact that it was first described in 1922 by Widal et 
al.
10, the pathophysiology of AERD is only partially understood 
and is not the focus of this review; however two reviews on this 
Aspirin-Exacerbated Respiratory Disease:  
Evaluation and Management
Rachel U. Lee,
1 Donald D. Stevenson
2*
1Division of Allergy, Asthma & Immunology, Naval Medical Center Portsmouth, Portsmouth, VA, USA
2Division of Allergy, Asthma & Immunology, Scripps Clinic, San Diego, CA, USA
topic were recently published by Stevenson.
2,11
Clinical features of AERD include onset of nasal congestion 
with anosmia and progression to chronic pansinusitis and na-
sal polyps which re-grow rapidly after surgery.
2,7 Nocturnal na-
sal obstruction with sleep deprivation fatigue occurs routinely 
in these patients. Asthma may precede the upper airway dis-
ease or develop later. CT or plain radiographs of the sinuses re-
veal complete opacification in nearly all AERD patients.
2,12 Nor-
mal imaging of the sinuses essentially rules out the diagnosis of 
AERD.
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Diagnosis of AERD
Aspirin challenge is the gold standard for diagnosing AERD.
1,2,13 
There are four routes of provocation challenges: oral, bronchial 
inhalation, nasal inhalation and intravenous.
13-17 In the United 
States oral aspirin challenges are performed. The protocol used 
at the Scripps Clinic is found in Table 2.
History of an asthma attack following ingestion of aspirin or 
other NSAIDs is suggestive and sometimes diagnostic. Howev-
er, 16% of patients who believed they had AERD, based upon a 
historical asthma attack after ingesting aspirin/NSAID, under-
went negative oral aspirin challenges and therefore, did not 
meet criteria for AERD.
18 On the other hand, in that same study, 
of patients who had nasal polyps, chronic sinusitis, asthma and 
were avoiding aspirin and NSAIDs, only 43% had positive oral 
aspirin challenges.
18 Thus, AERD is both over diagnosed (coin-
cidental history) or under diagnosed (no prior exposure to as-
pirin or COX-1 inhibitor during the time of the inflammatory 
respiratory disease).
TREATMENT OPTIONS FOR AERD
Avoidance or desensitization
Once patients are diagnosed, management options are limit-
ed to either complete avoidance of COX-1 inhibiting drugs or 
aspirin desensitization and continuous aspirin therapy.
2,13 In 
order to completely avoid COX-1 inhibitors, it is essential that 
clinicians are familiar with cross-reacting NSAIDS that inhibit 
COX-1 (Table 1) and that they educate patients on avoidance of 
all the various cross-reacting NSAIDS. On the other hand, it is 
important to note that there are other NSAIDs that either par-
tially inhibit COX-1 or are selective for COX-2, such as celecox-
ib, which lacks cross-reactivity with COX-1 inhibitors (Table 1). 
Well designed studies have shown that therapeutic doses of selec-
tive COX-2 inhibitors do not cross react with aspirin or other NSAIDs 
and therefore, can safely be given to patients with AERD.
19-21 Due to 
the rare possibility of other types of reaction to COX-2 inhibi-
tors, we recommend giving the first full dose in the physician’s 
office.
Avoidance of aspirin is not always possible due to need for as-
pirin in the management cardiovascular diseases. In addition, 
even with avoidance of aspirin and NSAIDs, AERD patients 
Table 1.  Four classes of NSAIDs based upon their pharmacologic function
1. Strong inhibitors of COX-1. Universal cross-reactions between these 
non steroidal anti-inflammatory drugs (NSAIDs) occur. At high 
concentration, inhibit COX-2.
Generic Generic
Piroxicam Mefanamic acid
Indomethacin Flurbiprofen
Sulindac Difluinisal
Tolmetin Ketoprofen
Ibuprofen Diclofenac
Naproxen Ketorolac
Naproxen sodium Etodolac
Fenoprofen Nabumetone
Oxaprozin Acetylsalicylic acid
2.   NSAIDs that are poor inhibitors of COX-1. At high concentrations 
minimal inhibition of COX-1, without inhibition of COX-2.
Acetaminophen (paracetamol)
Salsalate
3.   NSAIDs that preferentially inhibit COX-2 at lower doses but partially 
inhibit COX-1 when higher doses are given.
Nimesulide
Meloxicam
4.   Selective COX-2 inhibitors preferentially inhibit COX-2. At prescribed 
doses, no inhibition of COX-1 occurs.
Celecoxib
*
Rofecoxib
†
Valdecoxib
†
Etoricoxib
‡
Parecoxib
‡
Lumiracoxib
‡
* Available worldwide; 
†removed from the world market 2004 and 2005; 
‡ avail-
able outside the USA.
Table 2.  Oral aspirin challenges in patients with suspected aspirin exacerbat-
ed respiratory disease
Time Day 0 (or 1) 
* Day 1 (or 2) Day 2 (or 3)
8 AM Placebo 20-40 mg
† 100-160 mg
11 AM Placebo 40-60 mg 160-325 mg
2 PM Placebo 60-100 mg 325 mg
‡
* A placebo challenge can be conducted the week before. Alternatively, if the pa-
tient’s baseline FEV1 is the same as their prior best value and they have not 
used their albuterol rescue inhaler in the past week, you can skip the one day 
placebo challenge. 
†Using a pill cutter, 81 mg ASA tablet can be cut into a half 
or a fourth. 
‡If patient has not reacted to 325 mg of ASA, they will not react to 
650 mg. Therefore, if no reaction occurs in 3 hours after ASA 325 mg call it a 
negative challenge.
(1) Measure FEV1 every hour and wait three hours between doses.
(2) FEV1 should be at least 1.5 L and > 60 % of predicted.
(3) Reactions can be:
a. Naso-ocular alone
b. Naso-ocular and a 15% or > decline in FEV1 (Classic reaction)
c. Lower respiratory reaction only (FEV1 declines by >20%)
d. Laryngospasm with or without a, b, c (flat or notched inspiratory curve)
e. Systemic reaction:  hives, flush, gastric pain, hypotension
(4) Aspirin desensitization
a. After a reaction has been treated and resolved go to b.
b. Repeat the ASA provoking dose.
c. If no reaction, continue to escalate the doses as above.
d. At 325 mg of ASA, desensitization is always completed.
e. Give 650 mg as first dose and then treat with 650 mg bid.Aspirin-Exacerbated Respiratory Disease AAIR 
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usually experience progressive airways disease, despite aggres-
sive surgical intervention and topical or systemic anti-inflam-
matory treatment with corticosteroids and leukotriene modifi-
ers.
1,2,7,8 Therefore, the purpose of this review will be to discuss 
the specific issues related to aspirin desensitization, the clinical 
benefits, patient selection, aspirin dosing, potential adverse re-
actions and newer methods that may improve on current pro-
tocols for aspirin desensitization.
CLINICAL EFFECTIVENESS AND THE BENEFITS OF 
ASPIRIN DESENSITIZATION IN AERD
Why recommend aspirin desensitization and therapy?
Multiple studies have shown that desensitization and daily 
treatment with aspirin can significantly improve overall symp-
toms and quality of life, decrease formation of nasal polyps and 
sinus infections, reduce the need for oral corticosteroids and si-
nus surgery and improve nasal and asthma scores in patient 
with AERD at both 6 months and after one year of therapy 
(P<0.0001).
22-25 In a study from an otolaryngology clinic com-
paring outcomes of AERD patients who had surgery with aspi-
rin desensitization versus surgery alone, none of the aspirin de-
sensitized patients needed revision of their surgery, while 80% 
of the patients who did not undergo desensitization required 
additional surgery over a 2 year period (P=0.003).
26
How soon can you expect clinical improvement?
Significant clinical improvement is seen in as little as 4 weeks 
after treatment with nasal scores, sense of smell and asthma 
scores improving significantly (P<0.0001) and for those taking 
systemic corticosteroids, prednisone doses decrease from an 
average of 10.7 mg to 5.9 mg daily (P=0.0003).
27 From personal 
experience, there is a marked flattening of nasal membranes 
immediately after aspirin desensitization and many patients of-
ten note improvement in congestion and sense of smell within 
24-48 hours after completing aspirin desensitization. Improve-
ment in smell is more complicated, since the mechanism of 
compression of olfactory nerves by inflamed nasal tissues leads 
to nerve damage. Even when mucosal tissues return to normal, 
olfactory nerves may not regenerate.
Aspirin desensitization is cost effective
In addition to the clinical effectiveness of aspirin therapy, 
Shaker et al.
28 performed a healthcare cost analysis to model 
the costs of aspirin desensitization for therapeutic and prophy-
lactic use and found it to be cost-effective, even when factoring 
in the up front cost of aspirin desensitization. From an econom-
ic perspective, there is a substantial reduction of medical and 
surgical costs in the years following aspirin desensitization and 
daily aspirin treatment. Aspirin is also much less expensive for 
both treatment of primary and secondary prophylaxis in car-
diovascular disease compared to other anti-platelet agents.
28
PATIENT SELECTION AND OPTIMIZING DESENSITIZATION
Who should be desensitized?
Most patients with AERD will benefit clinically from desensiti-
zation as described earlier, however this treatment is particular-
ly helpful in patients who have suboptimal control with current-
ly available pharmacotherapy or if they require multiple opera-
tions due to re-growth of nasal polyps or intractable sinus dis-
ease.
29,30 Also, this procedure is indicated in AERD patients who 
require aspirin or NSAIDs for concomitant cardiovascular dis-
eases, arthritis, or other medical indications (Table 3).
29,30
Clinical factors to consider in optimizing ASA desensitization
It is important to note that AERD patients often have co-exist-
ing and provoking factors for upper and lower airway inflamma-
tion, including allergic rhinosinusitis, infections, gastroesopha-
geal reflux disease, exercise-induced asthma, etc.
2 Therefore, cli-
nicians must recognize these additional provoking factors and 
aggressively treat them in order to optimize management. Pa-
tients with concomitant allergic rhinitis and asthma should be 
maintained and stable on antihistamines, topical steroids, leu-
kotriene modifiers and immunotherapy. Sometimes omali-
zumab needs to be added to control this important co-morbid 
condition. Consider aggressive treatment of underlying gastro-
esophageal reflux disease with proton pump inhibitors or even 
Nissen fundoplication in severe cases recalcitrant to medical 
management. In addition, if patients have significant polyp or 
sinus disease, we routinely recommend surgical debulking 2-4 
weeks prior to aspirin challenge and desensitization; we find 
that aspirin treatment works best in preventing new polyp for-
mation. Although some patients experience marked regression 
of previously formed nasal polyps (Table 3), it is not possible to 
predict prospectively which patients might enjoy that benefit 
and to what extent that benefit might occur.
Premedication for aspirin challenge and desensitization
Most AERD patients synthesize excessive leukotrienes and se-
verity of respiratory disease corresponds with the baseline pro-
duction of leukotrienes.
31,32 In addition, AERD patients express 
more cysteinyl LT1 receptors on their inflammatory cells.
33 Aspi-
rin and inhibitors of COX-1 divert arachidonic acid toward the 
lipoxygenase pathway, hence causing additional overproduction 
of inflammatory mediators.
34 Interestingly, despite the role of 
leukotrienes in AERD, medications that modify this pathway, 
such as zileuton, a 5-lipoxygenase inhibitor, or inhibit cysteinyl 
leukotriene receptor (CysLT1), such as montelukast or zafirlu-
kast, do not prevent upper airway reactions during aspirin chal-
lenges.
35 Rather, CysLT1 inhibitors primarily prevent or attenu-
ate bronchospasm.
35 Studies have demonstrated that leukotri-
ene modifier drugs positively impact treatment of AERD and, 
as we will discuss, also improve safety of aspirin challenges.
36-38
We recommend that all patients have baseline spirometry Lee et al.
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showing FEV1 values to be more than 60% of predicted and at 
least 1.5 L. If they are not already taking a leukotriene modifier, 
we start either montelukast, zileuton or both prior to aspirin 
challenge. Patients are instructed to continue oral and topical 
corticosteroids and long-acting bronchodilators. We do ask that 
patients discontinue their antihistamines, decongestants and 
short-acting inhaled beta- agonists prior to aspirin challenge. 
These medications may mask a potential response and thus pre-
vent diagnosis (Table 2). As an aspirin challenge and provoca-
tive reaction is the gold standard for diagnosis, it is necessary to 
measure a naso-ocular or bronchial reaction and thus confirm a 
diagnosis of AERD.
Inpatient or outpatient oral aspirin desensitization
Over 1,400 patients have successfully undergone aspirin chal-
lenge and desensitizations at the Scripps Clinic without any 
deaths or serious complications. In the past, the assumption was 
that the historical reactions to aspirin/NSAIDs should dictate the 
location of the aspirin desensitization procedure. The rational 
was that a bad reaction to aspirin 650 mg (or equivalent doses 
of NSAID) that required hospital intervention predicted a se-
vere asthma attack during oral aspirin challenges and therefore 
should be conducted in a hospital ICU. However, Williams et 
al.
39 at our institution compared the severity of prior aspirin/
NSAID reactions and the degree of asthma induced during oral 
aspirin challenges and found that there was no correlation. A 
small number of severe reactions occurred during oral ASA 
challenges but they were just as likely to occur in patients with 
mild historical reactions. Furthermore, none of the “severe” re-
actions (FEV1 dropping >30% from baseline) required any more 
treatment than is available in all allergy outpatient offices.
39 
None required intubation or transfer to an ICU. Our explana-
tion for the above is linked to dose response reactions. Histori-
cal reactions were induced by full therapeutic doses of aspirin 
or NSAIDs, compared to the average provoking dose of aspirin 
of 60 mg during oral aspirin challenges. Furthermore, the his-
torical reactions may have occurred many years previously, usu-
ally without anti-leukotriene coverage. Also, the inflammatory 
respiratory disease may have changed over the years. In conclu-
sion, historical reaction severity is not predictive of the degree of 
bronchospasm which might occur during controlled oral aspi-
rin challenges.
39
With experienced providers and staff, outpatient oral challeng-
es are as safe as inpatient challenges and much more cost effec-
tive. At Scripps Clinic, beginning in 2003, we switched from in-
patient (General Clinical Research Center) to outpatient Allergy 
Division offices and have conducted all oral aspirin challenges 
in our outpatient with one exception – inpatient desensitization 
should be strongly considered in patients receiving beta-block-
ers, recent myocardial infarction, and/or with severe or uncon-
trolled asthma. The only setting where we have encountered 
this need for ICU aspirin desensitization is with asthmatic pa-
Table 3.  Factors to consider in optimizing safe and effective aspirin desensiti-
zation in aspirin exacerbated respiratory disease
Safety
• Stable asthma
• Pretreatment
•  Protocol medication  pre-
cautions
– FEV1>60% and within 10% of best prior value
–   Continue all medications for upper and lower 
airways, including inhaled and intranasal ste-
roids
–   Start leukotriene modifier drug 2-4 weeks prior 
to if not already taking it, i.e. montelukast 10 mg 
daily
–   Oral corticosteroids if necessary
–   Stop antihistamines and decongestants 48hr 
prior to aspirin challenge
–   Stop short acting bronchodilator on day of chal-
lenge
Prior to desensitization
•  Patient selection
•  Sinus surgery
•  Continued use of medica-
tions
•  Treat concomitant condi-
tions that may  
affect efficacy
*
–   Intractable symptoms despite medical treat-
ment
–   Recurrent nasal polyps requiring multiple sur-
geries
–   Frequent or daily systemic corticosteroids are 
required to control nasal symptoms and/or asth-
ma
–   Additional medical indication for aspirin 
–   Debulking nasal polyposis 2-4 weeks before 
ASA desensitization is ideal
–   As indicated
–   Allergic rhinitis and asthma
–   Asthma (other mechanisms) particularly
–   Gastroesophageal reflux
–   Infections (sinuses and bronchial)
After aspirin desensitization 
•  Appropriate aspirin dose
•  Manage common side ef-
fects
•  Provide anticipatory guid-
ance
•  Continue to treat concom-
itant diseases
*
–   Start 650 mg bid, then titrate down to 325 mg 
bid (to least clinically effective maintenance 
dose)
–   Gastrointestinal prophylaxis
–   Treat aspirin induced urticaria with anti-hista-
mines
–   Perioperative aspirin dosing
–   Interruption of aspirin therapy
  
–   As above
*  Allergic rhinitis (nasal steroids, antihistamines, leukotriene modifiers, decon-
gestants, immunotherapy, saline irrigation), asthma (inhaled steroids, long act-
ing beta-agonists, leukotriene modifiers, anti-IgE therapy, immunotherapy for 
allergic asthma, systemic corticosteroids), gastroesophageal reflux (proton 
pump inhibitors, H2-antihistamines, if severe – consider fundoplication), infec-
tions (antibiotics).Aspirin-Exacerbated Respiratory Disease AAIR 
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tients admitted for an acute coronary syndrome urgently requir-
ing aspirin therapy for either coronary stent or bypass surgery.
Although aspirin desensitization is beneficial in most patients 
with AERD, contraindications to aspirin desensitization include 
pregnancy, unstable asthma, gastric ulcers or bleeding disorders. 
We screen out patients with the above conditions and require 
that all patients sign informed consents prior to challenge and 
desensitization.
Oral aspirin challenge and desensitization protocol
Many variations of the oral aspirin challenge have been pub-
lished.
2,30 Hope et al.
40 recently published a rational approach to 
aspirin challenge dosing which reviewed 420 aspirin desensiti-
zations at the Scripps Clinic and used historical data to en-
hance the efficiency of the desensitization protocol. We found 
that most reactions occurred at 45 to 100 mg of aspirin and no 
patients reacted after the 650 mg dose.
40 The average time to re-
action was 102 minutes after last aspirin dose.
40 Based on this ra-
tionale, we start with 20 to 40 mg of aspirin and advance every 
three hours (Table 2), and often complete the protocol in 2.5 
days, 3 hours after the 325 mg asprin dose.
40 If at any time a reac-
tion occurs in the larynx or the bronchi, reactions are treated be-
fore continuation and the provocation dose is then repeated. If 
the reaction is limited to the nasal membranes, oxymetazoline 
nasal spray is used and the challenge is then continued with the 
next dose of aspirin.
ASPIRIN DOSAGES AND MAINTENANCE THERAPY AFTER 
SUCCESSFUL DESENSITIZATION
Patient specific optimal doses of aspirin cannot be predictable. 
This topic was evaluated by Lee et al.
41 We found that no clinical 
distinguishing factor determined whether a patient needs 650 
mg twice daily or 325 mg twice daily.
41 Therefore, we recom-
mend aspirin 1,300 mg daily (usually 650 mg bid) for one 
month. If there is significant improvement in upper and lower 
airway symptoms, we decrease by one tablet (325 mg) monthly 
to either 650 mg AM and 325 mg at night or ideally 325 mg bid 
(Table 3).
41 A dose as low as 81 mg of aspirin can maintain the 
desensitized state, which may be sufficient for patients who 
need only cardiovascular prophylaxis, but is usually suboptimal 
with respect to blocking inflammatory tissues in the respiratory 
tract.
30 In a small study by Rozsasi et al.
42, AERD patients were 
desensitized with aspirin and then randomized to receive ei-
ther aspirin 100 mg daily or 300 mg daily. One year later, careful 
re-examination revealed no polyp reformation in the any of the 
300 mg daily group but nasal polyp reformation in all 7 of the 
patients treated with aspirin 100 mg daily.
42 The same authors 
in an open study of 39 additional AERD patients, all of whom 
were treated with aspirin 300 mg daily, and none of these pa-
tients reformed nasal polyps at the end of one year of treatment.
42 
Maintenance treatment with aspirin should be at least 325 mg 
daily and ideally twice a day.
Since the introduction of leukotriene modifiers in the late 1990s, 
there have been several patients who were previously aspirin 
challenge positive, who subsequently stopped their aspirin ther-
apy and were rechallenged while taking montelukast. They did 
not have a measureable reaction. However after taking aspirin 
325 mg, they showed clinical flattening of the nasal turbinates 
and improvement of their nasal and asthma scores at one month 
after daily treatment with aspirin 650 mg twice daily (unpub-
lished reports). Due to the potential of “silent desensitization” 
(under the blocking influence of montelukast), we recommend 
that all patients with history consistent with AERD continue as-
pirin for one month to evaluate clinical improvement. We are 
not aware of any studies that show that aspirin tolerant asthmat-
ics receive any therapeutic benefit from aspirin treatment. Al-
though we have proven silent desensitization in a few patients 
and thus have anecdotal evidence that silent desensitization 
can occur, concomitantly with or even without montelukast, 
further systematic studies are needed in order to better charac-
terize this phenomena.
RISKS OF ORAL ASPIRIN CHALLENGES
Aspirin desensitization is highly effective, but underutilized. 
The main barrier to more widespread use of aspirin desensiti-
zation is the potential for aspirin induced severe bronchospasm, 
laryngospasm, and/or extra-respiratory side effects (cutaneous 
and gastric).
39
A recent study analyzing 210 patients with suspected AERD 
found that naso-ocular reactions occurred in 90% and lower 
airway reactions (bronchial/laryngeal) occurred in 43%.
39 Ex-
tra-pulmonary reactions were noted; gastrointestinal in 23% 
and cutaneous in 10%.
39 Reactions during the challenges and 
desensitization are treated aggressively as indicated below. 
Bronchial reactions may be treated with inhaled beta-agonists. 
Laryngeal reactions respond to nebulized racemic epinephrine 
or intramuscular epinephrine. Nasal and ocular reactions are 
successfully treated with oral and topical antihistamines, mast 
cell stabilizers and decongestants. Aspirin induced flushing, ur-
ticaria, angioedema and pruritis may be treated with oral or in-
travenous antihistamines. Gastric symptoms, which include 
nausea, vomiting and abdominal cramping pain respond to 
oral or intravenous H2-antihistamines. For systemic reactions, 
intravenous fluid resuscitation and intramuscular epinephrine 
are available but rarely needed. In the 1,400 patients in whom 
we have conducted oral aspirin challenges, 3 (0.002%) experi-
enced systemic reactions, which included hypotension. All 
three, responded quickly to one intramuscular injection of epi-
nephrine.
Long term safety profile
In a group of 172 patients, who had undergone aspirin desen-Lee et al.
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sitization and treated with daily aspirin 650 mg twice daily for a 
year, 24 (14%) discontinued ASA treatment due to known side 
effects (i.e. gastric pain or bleeding, non-gastrointestinal bleed-
ing, such as epistaxis, and urticaria).
22 Eleven percent of patients 
stopped due to poor response and other reasons (i.e. planned 
surgeries, rash, death from other causes, etc).
22 Of the remain-
ing 126 patients who were continued on aspirin for a year, 110 
(87%) benefitted from aspirin therapy.
22
In the group of 16 “non responders” , 12 had concomitant se-
vere allergic respiratory disease to dust mutes and pets in the 
house. None were on immunotherapy and the study preceded 
the availability of omalizumab. The study design did not antici-
pate or account for this variable which may have negated the 
therapeutic effect of aspirin desensitization treatment.
There is a refractory period of about 48 to 72 hours following 
aspirin desensitization; this is maintained by continued aspirin 
therapy. Therefore, if there are brief interruptions to therapy 
(<48 hours) due to surgery or illness, aspirin may be restarted. 
However, if there is greater than a 48 hour disruption from treat-
ment, we recommend repeat desensitization. The authors are 
aware of one patient, from another center, who lost the desensi-
tized state after 24 hours.
NEW METHODS AND DOSING RATIONALE
In addition to the immediate risks of the procedure, another 
barrier to more widespread use is that it is time consuming, of-
ten lasting up to 3 days and longer if there are reactions requir-
ing treatment and repeat doses. As mentioned earlier, Hope et 
al.
40 published a rationale approach to dosing during oral chal-
lenges and desensitization which shortened the protocol from 
3 to 2.5 days.
We recently presented a novel method of enhancing the chal-
lenge and desensitization process which was recently accepted 
for publication.
43 The conception for this research evolved when 
White et al.
44 demonstrated the use of intranasal ketorolac, in 
place of lysine-aspirin, as a nasal challenge provoking drug.
In Asia and Europe, intranasal lysine-aspirin is used as a diag-
nostic and therapeutic agent for AERD.
45,46 Lysine-aspirin is not 
commercially available in the United States. Therefore, we were 
previously limited to only oral aspirin for challenge and treat-
ment. However, we showed that intranasal ketorolac (Toradol
®) 
is a safe and effective alternative for diagnosing AERD.
44 In our 
study by White et al.
44, there were several patients who had no 
subsequent reactions to oral aspirin challenges immediately fol-
lowing positive ketorolac challenges. We hypothesized that this 
procedure could potentially improve existing protocols for aspi-
rin challenges and desensitization. In our study, we found that 
patients had significantly less laryngospasm and gastric side ef-
fects than a control group undergoing standard oral aspirin 
challenges.
43 Perhaps as important, compared to an aspirin oral 
challenge control group, this new protocol significantly de-
creased the duration of the procedure as well (1.5 vs. 2.5 days of 
challenges and desensitization).
43 This significantly decreases 
the cost of the procedure by one day or 40%. Currently at the 
Scripps Clinic, unless there is a contraindication to the proce-
dure, such as complete nasal obstruction from polyps (which 
rarely occurs since pre procedure protocol calls for surgical de-
bulking), AERD patients undergo this newer protocol using in-
tranasal ketorolac and modified oral aspirin. See Figure for de-
tailed instructions on how to prepare the nasal ketorolac and 
proceed with this protocol.
CONCLUSIONS
Strong evidence supports the safety and clinical effectiveness 
of aspirin desensitization in the treatment of AERD. Aspirin de-
Figure.  Intranasal ketorolac protocol and directions for ketorolac solution 
preparation
Time Intranasal ketorolac and modified oral aspirin challenge
Day 1
*
  8:00 AM 1 spray
† (1 in one nostril)
  8:30 2 sprays
† (1 in each nostril)
  9:00 4 sprays
† (2 in each nostril)
  9:30 6 sprays
† (3 in each nostril)
  10:30 60 mg aspirin
†
  12:00 60 mg aspirin
†
  3:00 PM Instructions and discharge
Day 2
  8:00 AM 150 mg
†
  11:00 325 mg
†
  2:00 PM Instructions and discharge
*To prepare nasal ketorolac solution: 
1.   Take ketorolac tromethamine (60 mg/2 mL) and preservative free normal 
saline (2.75 mL). 
2. Mix in an emptied Nasocort AQ
® spray bottle.
3.   Prime with 5 sprays before use, then each spray actuates 1.26 mg of solu-
tion.
4.   Instruct patient and medical personnel to tilt head down while spraying and 
sniff gently to avoid swallowing solution.
† Clinical and objective evaluation with spirometry performed before each dose 
and as needed.
If there is no reaction 3 hours after the 325 mg dose of aspirin, this is a negative 
challenge.
Reactions can be:
– Naso-ocular alone
– Naso-ocular and a 15% or more decline in FEV1 (Classic reaction)
– Lower respiratory reaction only (FEV1 declines by >20%)
– Laryngospasm with or without a, b, c (flat or notched inspiratory curve)
–     Systemic reaction:  hives, flush, gastric pain, hypotension
Aspirin desensitization:
a. After a reaction has been treated and resolved, repeat provoking dose.
b. If no reaction, continue to escalate the doses as above.
c. At 325 mg of aspirin, desensitization is always completed.Aspirin-Exacerbated Respiratory Disease AAIR 
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sensitization reduces nasal congestion and polyp formation, 
improves respiratory symptoms and reduces the need for sur-
gery and requirements for on-going medications. As awareness 
of AERD increases, greater availability of aspirin desensitization 
is required to successfully manage this condition. In addition, 
continued research efforts in understanding the pathophysiol-
ogy, the phenomenon of “silent desensitization” , treatment op-
tions, and possibly prevention are needed to better manage this 
condition.
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